[Studies on the bioequivalence of canrenone using pharmacokinetic data and clinical effects].

Canrenon, an active metabolite of spironolactone, and the combination of Canrenon with hydrochlorothiazide (HCT) were examined on patients with essential hypertension, cardial oedemas and oedemas of different origin, and than compared to a product available on the market. A correlation of the clinical effect (e.g. systolic blood pressure) with the morning steady state-data (blood values of Canrenon and HCT) has been achieved. The new preparations showed a good resorption in the gastro-intestinal tract. For an equivalent clinical effect, less Canrenon substance has been needed. A therapeutically satisfactory result has been reached with the administered dosage of both Canrenon and the comparison group. In the combination the higher dosage level should be chosen.